Skip to content
PeptideAgent

Peptides for peripheral and small fiber neuropathy: what the evidence shows

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

At a glance

ARA 290 (cibinetide), a peptide engineered from erythropoietin, improved neuropathic symptoms and corneal nerve fiber measures in small placebo controlled trials in sarcoidosis and type 2 diabetes, but it is not approved anywhere. Standard care treats the cause and uses duloxetine, pregabalin, gabapentin, or tricyclic antidepressants for pain.

Evidence: Strongest: Human RCT evidence2 peptides gradedVerified: Verified Sep 22, 2026

Do peptides help with peripheral and small fiber neuropathy?

2 peptides are graded for peripheral and small fiber neuropathy on this page. The strongest grade is human RCT evidence, for ARA-290 (cibinetide). Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.

What is the standard of care for peripheral and small fiber neuropathy?

Identify and treat the cause (diabetes, vitamin B12 deficiency, alcohol, thyroid disease, medications); foot care and fall prevention; duloxetine, pregabalin, gabapentin, or tricyclic antidepressants for neuropathic pain; topical capsaicin or lidocaine for focal pain.

Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.

Which peptides have been studied for peripheral and small fiber neuropathy?

Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.

Peptides studied for Peripheral and small fiber neuropathy with evidence grades
PeptideEvidence for this useNote
ARA-290 (cibinetide)Evidence: Human RCT evidenceIn 64 patients with sarcoidosis associated small fiber loss, 4 mg daily increased corneal nerve fiber area versus placebo; a smaller type 2 diabetes trial improved neuropathy pain scores; not approved. [1] [2]
ThymulinEvidence: Animal-only evidenceA thymulin related peptide reduced pain hypersensitivity in rodent models; no human neuropathy study. [5]

Frequently asked questions

Which peptide has the strongest evidence for peripheral and small fiber neuropathy?

ARA-290 (cibinetide) has the strongest evidence among the peptides graded here, at human RCT evidence. In 64 patients with sarcoidosis associated small fiber loss, 4 mg daily increased corneal nerve fiber area versus placebo; a smaller type 2 diabetes trial improved neuropathy pain scores; not approved. [1] [2]

Is any peptide FDA approved for peripheral and small fiber neuropathy?

No. None of the peptides graded for peripheral and small fiber neuropathy is an FDA approved drug, so any use is outside an approved label and depends on the compounding and research status shown on each peptide page. [6]

Has any peptide been tested in a randomized trial for peripheral and small fiber neuropathy?

Yes, for ARA-290 (cibinetide). Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [1] [2]

Sources

  1. [1]Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot studyPubMed 23168581, 2012
  2. [2]Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic painPubMed 28475703, 2017
  3. [3]ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetesPubMed 25387363, 2015
  4. [4]Dahan A et al. ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opin Investig Drugs 2014PubMed 24555851, 2014
  5. [5]Targeting inflammatory components in neuropathic pain: The analgesic effect of thymulin related peptidePubMed 30503917, 2019
  6. [6]Drugs@FDA: FDA-approved drugs databaseFDA